New targets of urocortin-mediated cardioprotection

Journal of Molecular Endocrinology

Volumn 45, Issue 2, 2010, Pages 69-85

  Barry, Seán P ^a   Lawrence, Kevin M ^b   McCormick, James ^a   Soond, Surinder M ^c   Hubank, Mike ^a   Eaton, Simon ^a   Sivarajah, Ahila ^d   Scarabelli, Tiziano M ^e   Knight, Richard A ^a   Thiemermann, Christoph ^d   Latchman, David S ^a   Townsend, Paul A ^f   Stephanou, Anastasis ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; G PROTEIN COUPLED RECEPTOR; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; RAC2 PROTEIN; RAP1 PROTEIN; TRANSCRIPTION FACTOR NRF1; UROCORTIN I; UROCORTIN II; X LINKED INHIBITOR OF APOPTOSIS; CARDIOTONIC AGENT; UROCORTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; ENZYME ACTIVATION; GENE CONTROL; GENE EXPRESSION; HEART INFARCTION; HEART PROTECTION; IN VIVO STUDY; ISCHEMIA; MALE; METABOLISM; MICROARRAY ANALYSIS; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REPERFUSION INJURY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; HEART MUSCLE CELL; HUMAN; MOLECULAR GENETICS; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; CARDIOTONIC AGENTS; CELLS, CULTURED; ENZYME ACTIVATION; FREE RADICALS; GENE EXPRESSION; HUMANS; MALE; MICROARRAY ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; UROCORTINS;

EID: 77957373348     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0148     Document Type: Article

References (59)

1. Baigent SM 2001 Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response. Peptides 22 809-820.
2. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW & Peterson KL 2004 The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. PNAS 101 3697-3702.
3. Bertrand L, Ginion A, Beauloye C, Hebert AD, Guigas B, Hue L & Vanoverschelde JL 2006 AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. American Journal of Physiology. Heart and Circulatory Physiology 291 H239-H250.
4. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, Yellon DM & Latchman DS 2000 Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. Journal of Biological Chemistry 275 8508-8514.
5. Brar BK, Stephanou A, Knight R & Latchman DS 2002 Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. Journal of Molecular and Cellular Cardiology 34 483-492.
6. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjos OD, Latchman DS, Lee KF & Vale W 2004 Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145 24-35.
7. Carvajal K, Zarrinpashneh E, Szarszoi O, Joubert F, Athea Y, Mateo P, Gillet B, Vaulont S, Viollet B, Bigard X et al. 2007 Dual cardiac contractile effects of the α2-AMPK deletion in low-flow ischemia and reperfusion. American Journal of Physiology. Heart and Circulatory Physiology 292 H3136-H3147.
8. Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ & Latchman DS 2003 Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. Journal of Molecular and Cellular Cardiology 35 1295-1305.
9. Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A, Knight RD, Hsu SY, Hsueh AJ & Latchman DS 2005 Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochemical and Biophysical Research Communications 328 442-448.
10. Chen L, Kwong M, Lu R, Ginzinger D, Lee C, Leung L & Chan JY 2003 Nrf1 is critical for redox balance and survival of liver cells during development. Molecular and Cellular Biology 23 4673-4686.
11. Davidson SM, Rybka AE & Townsend PA 2009 The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family. Biochemical Pharmacology 77 141-150.
12. De Kloet ER 2003 Hormones, brain and stress. Endocrine Regulations 37 51-68.
13. Diebold BA & Bokoch GM 2001 Molecular basis for Rac2 regulation of phagocyte NADPH oxidase. Nature Immunology 2 211-215.
14. Diotte NM, Xiong Y, Gao J, Chua BH & Ho YS 2009 Attenuation of doxorubicin-induced cardiac injury by mitochondrial glutaredoxin 2. Biochimica et Biophysica Acta 1793 427-438.
15. Dyck JR & Lopaschuk GD 2006 AMPK alterations in cardiac physiology and pathology: enemy or ally? Journal of Physiology 574 95-112.
16. Eckelman BP, Salvesen GS & Scott FL 2006 Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Reports 7 988-994.
17. Frost JA, Xu S, Hutchison MR, Marcus S & Cobb MH 1996 Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members. Molecular and Cellular Biology 16 3707-3713.
18. Gonzalez-Garcia A, Pritchard CA, Paterson HF, Mavria G, Stamp G & Marshall CJ 2005 RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7 219-226.
19. Hillhouse EW & Grammatopoulos DK 2006 The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocrine Reviews 27 260-286.
20. Hillhouse EW, Randeva H, Ladds G & Grammatopoulos D 2002 Corticotropin-releasing hormone receptors. Biochemical Society Transactions 30 428-432.
21. Iwaki K, Chi SH, Dillmann WH & Mestril R 1993 Induction of HSP70 in cultured rat neonatal cardiomyocytes by hypoxia and metabolic stress. Circulation 87 2023-2032.
22. Kageyama K, Hanada K, Moriyama T, Imaizumi T, Satoh K & Suda T 2007 Differential regulation of CREB and ERK phosphorylation through corticotropin-releasing factor receptors type 1 and 2 in AtT-20 and A7r5 cells. Molecular and Cellular Endocrinology 263 90-102.
23. Kuperman Y & Chen A 2008 Urocortins: emerging metabolic and energy homeostasis perspectives. Trends in Endocrinology and Metabolism 19 122-129.
24. Kwong M, Kan YW & Chan JY 1999 The CNC basic leucine zipper factor, Nrf1, is essential for cell survival in response to oxidative stress-inducing agents. Role for Nrf1 in gamma-gcs(l) and gss expression in mouse fibroblasts. Journal of Biological Chemistry 274 37491-37498.
25. Lawrence KM, Chanalaris A, Scarabelli T, Hubank M, Pasini E, Townsend PA, Comini L, Ferrari R, Tinker A, Stephanou A et al. 2002 K(ATP) channel gene expression is induced by urocortin and mediates its cardioprotective effect. Circulation 106 1556-1562.
26. Lawrence KM, Scarabelli TM, Turtle L, Chanalaris A, Townsend PA, Carroll CJ, Hubank M, Stephanou A, Knight RA & Latchman DS 2003 Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression. FASEB Journal 17 2313-2315.
27. Lawrence KM, Kabir AM, Bellahcene M, Davidson S, Cao XB, McCormick J, Mesquita RA, Carroll CJ, Chanalaris A, Townsend PA et al. 2005 Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. FASEB Journal 19 831-833.
28. Lillig CH, Berndt C & Holmgren A 2008 Glutaredoxin systems. Biochimica et Biophysica Acta 1780 1304-1317.
29. Liu CN, Yang C, Liu XY & Li S 2005 In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. Canadian Journal of Physiology and Pharmacology 83 459-465.
30. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 402-408.
31. Luna L, Skammelsrud N, Johnsen O, Abel KJ, Weber BL, Prydz H & Kolsto AB 1995 Structural organization and mapping of the human TCF11 gene. Genomics 27 237-244.
32. Martinez V, Wang L, Million M, Rivier J & Tache Y 2004 Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25 1733-1744.
33. McCormick J, Barry SP, Sivarajah A, Stefanutti G, Townsend PA, Lawrence KM, Eaton S, Knight RA, Thiemermann C, Latchman DS et al. 2006 Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. FASEB Journal 20 2115-2117.
34. McDonald MC, Zacharowski K, Bowes J, Cuzzocrea S & Thiemermann C 1999 Tempol reduces infarct size in rodent models of regional myocardial ischemia and reperfusion. Free Radical Biology and Medicine 27 493-503.
35. Nagy N, Malik G, Tosaki A, Ho YS, Maulik N & Das DK 2008 Overexpression of glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis and necrosis. Journal of Molecular and Cellular Cardiology 44 252-260.
36. Ng LL, Loke IW, O'Brien RJ, Squire IB & Davies JE 2004 Plasma urocortin in human systolic heart failure. Clinical Science 106 383-388.
37. Ohtsuji M, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD & Yamamoto M 2008 Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. Journal of Biological Chemistry 283 33554-33562.
38. Parkes DG, Vaughan J, Rivier J, Vale W & May CN 1997 Cardiac inotropic actions of urocortin in conscious sheep. American Journal of Physiology 272 H2115-H2122.
39. Patel NS, Collin M & Thiemermann C 2004 Urocortin does not reduce the renal injury and dysfunction caused by experimental ischaemia/reperfusion. European Journal of Pharmacology 496 175-180.
40. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM & Vale WW 2002 Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. Journal of the American College of Cardiology 40 1495-1505.
41. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG & Richards AM 2005 Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. European Heart Journal 26 2055-2062.
42. Rademaker MT, Charles CJ & Richards AM 2007 Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. American Journal of Physiology. Heart and Circulatory Physiology 293 H1536-H1544.
43. Reiner A, Yekutieli D & Benjamini Y 2003 Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19 368-375.
44. Resch U, Schichl YM, Sattler S & de Martin R 2008 XIAP regulates intracellular ROS by enhancing antioxidant gene expression. Biochemical and Biophysical Research Communications 375 156-161.
45. Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ & Young LH 2004 AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. Journal of Clinical Investigation 114 495-503.
46. Russell JC, Whiting H, Szuflita N & Hossain MA 2008 Nuclear translocation of X-linked inhibitor of apoptosis (XIAP) determines cell fate after hypoxia ischemia in neonatal brain. Journal of Neurochemistry 106 1357-1370.
47. Sanges R, Cordero F & Calogero RA 2007 oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language. Bioinformatics 23 3406-3408.
48. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R, Ferrari R, Knight R & Latchman DS 2002 Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. Journal of the American College of Cardiology 40 155-161.
49. Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, Chen-Scarabelli C, Saravolatz L, Latchman D, Knight R et al. 2004 Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. Journal of the American College of Cardiology 43 865-874.
50. Schmittgen TD & Livak KJ 2008 Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 3 1101-1108.
51. Schulman D, Latchman DS & Yellon DM 2002 Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. American Journal of Physiology. Heart and Circulatory Physiology 283 H1481-H1488.
52. Sivarajah A, McDonald MC & Thiemermann C 2005 The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-g antagonist. Journal of Pharmacology and Experimental Therapeutics 313 896-901.
53. Sun LL, Cheng C, Liu HO, Shen CC, Xiao F, Qin J, Yang JL & Shen AG 2007 Src suppressed C kinase substrate regulates the lipopolysaccharide-induced TNF-α biosynthesis in rat astrocytes. Journal of Molecular Neuroscience 32 16-24.
54. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M, Kawase I & Hirota H 2005 AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Molecular and Cellular Biology 25 9554-9575.
55. Townsend PA, Davidson SM, Clarke SJ, Khaliulin I, Carroll CJ, Scarabelli TM, Knight RA, Stephanou A, Latchman DS & Halestrap AP 2007 Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. American Journal of Physiology. Heart and Circulatory Physiology 293 H928-H938.
56. Wettenhall JM, Simpson KM, Satterley K & Smyth GK 2006 affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics 22 897-899.
57. Yang LZ, Kockskamper J, Heinzel FR, Hauber M, Walther S, Spiess J & Pieske B 2006 Urocortin II enhances contractility in rabbit ventricular myocytes via CRF(2) receptor-mediated stimulation of protein kinase A. Cardiovascular Research 69 402-411.
58. Zhang H, Zhang R, Luo Y, D'Alessio A, Pober JS & Min W 2004 AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. Journal of Biological Chemistry 279 44955-44965.
59. Zhu C, Xu F, Fukuda A, Wang X, Fukuda H, Korhonen L, Hagberg H, Lannering B, Nilsson M, Eriksson PS et al. 2007 X chromosome-linked inhibitor of apoptosis protein reduces oxidative stress after cerebral irradiation or hypoxia-ischemia through up-regulation of mitochondrial antioxidants. European Journal of Neuroscience 26 3402-3410.